longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Citi Reaffirms Their Buy Rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252)

Tip Ranks
May 30, 2026 at 02:35 PM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Citi reaffirmed its Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252), setting a price target of HK$41.00, while the stock closed at HK$26.60. The broader analyst consensus for the company remains a Strong Buy with an average price target of HK$39.27.

In a report released on May 27, from Citi maintained a Buy rating on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H, with a price target of HK$41.00. The company’s shares closed yesterday at HK$26.60.

Memorial Day Sale – Claim 70% Off TipRanks

  • Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
  • Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter

Currently, the analyst consensus on Shanghai MicroPort MedBot (Group) Co., Ltd. Class H is a Strong Buy with an average price target of HK$39.27.

Login to unlock152characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
  • Apr 1, 2026 at 11:11 PMEli Lilly's Oral Weight-Loss Drug Foundayo Approved, the Only One That Can Be Taken Anytime Without Fasting
  • Mar 27, 2026 at 05:24 AMBuying Platforms, Selling Pipelines: Deconstructing the Innovation Logic of SINO BIOPHARM
  • Mar 26, 2026 at 07:03 AMThe Reality and Illusion of "AI Drug Discovery" XTALPI's Turnaround
  • Mar 23, 2026 at 12:09 PMStrong US Market! WuXi AppTec's 2025 Net Profit Attributable to the Parent Company Surged 105.2%, 2026 Revenue Growth Ex…

Related Stocks

MircroPort Medbot-B

MircroPort Medbot-B

HK02252

0.00%

Citigroup

Citigroup

USC

CITIGROUP INC 6.250 NON CUM SER II PFD WI

CITIGROUP INC 6.250 NON CUM SER II PFD WI

USC-R

LongbridgeAI